ICTRP Search Portal

Main

Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.

Register:	EUCTR
Last refreshed on:	9 October 2012
Main ID:	EUCTR2006-000658-27-SE
Date of registration:	11/10/2006
Prospective Registration:	Yes
Primary sponsor:	AstraZeneca AB
Public title:
Scientific title:	A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS)[PLATO – A Study of PLATelet inhibition and Patient Outcomes] - PLATO
Date of first enrolment:	30/11/2006
Target sample size:	18000
Recruitment status:	Not Recruiting
URL:	https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-000658-27
Study type:	Interventional clinical trial of medicinal product
Study design:	Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: yes Cross over: no Other: yes Other trial design description: double dummy If controlled, specify comparator, Other Medicinial Product: yes Placebo: no Other: no
Phase:

Countries of recruitment
Austria	Czech Republic	Denmark	Finland	France	Germany	Greece	Hungary
Italy	Netherlands	Portugal	Spain	Sweden	United Kingdom

Contacts

Name:
Address:
Telephone:
Email:
Affiliation:

Name:
Address:
Telephone:
Email:
Affiliation:

Key inclusion & exclusion criteria

Inclusion criteria:
1. Index event of non-ST or ST segment elevation ACS. The patient should be hospitalised for chest pain and potential ACS and the onset of the most recent cardiac ischaemic symptoms of the index event must occur within the 24 hours before randomisation and be documented by cardiac ischaemic symptoms of =10 minutes duration at rest AND (i, ii, or iii):

i) Persistent ST segment elevation =1mm (0.1 mV) in 2 or more contiguous leads and primary PCI planned
OR
ii) New or presumed new left bundle branch block (LBBB) and primary PCI planned
OR
iii) Cardiac ischaemic symptoms of =10 minutes duration at rest and at least 2 of the following 3 criteria (A-C):

A) ST segment changes on ECG indicative of ischaemia
B) Positive biomarker (Troponin I or -T or CK-MB) evidence of myocardial necrosis
C) Having at least one of the following risk factors: Aged 60 or over, Previous MI or CABG, Known multi-vessel coronary artery disease (CAD), Previous ischaemic stroke, TIA, carotid stenosis, or cerebral revascularisation, Diabetes mellitus, Peripheral arterial disease, Chronic renal dysfunction

2. Provision of signed informed consent form.
3. Male or female aged at least 18 years
4. Females of child-bearing potential who are willing to use 2 methods of contraception.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion criteria:
1. Contraindication or other reason that clopidogrel or AZD6140 should not be administered.
2. Index event is a complication of PCI
3. Patient has undergone PCI after the index event and before the first dose of study treatment
4. Oral anticoagulation therapy that cannot be stopped
5. Fibrinolytic therapy in the 24 hours prior to randomisation, or planned fibrinolytic
treatment following randomisation
6. Increased risk of bradycardic events
7. Patient requires dialysis
8. Known, clinically important thrombocytopenia
9. Known, clinically important anemia
10. Participation in another investigational drug or device study in the last 30 days
11. Pregnancy or lactation
12. Concomitant oral or intravenous therapy with strong CYP 3A inhibitors, CYP3A substrates with narrow therapeutic indices, or strong CYP3A inducers which cannot be stopped for the course of the study
13. Any other condition which in the opinion of the investigator, may either put the patient at risk or influence the result of the study
14. Involvement in the planning and conduct of the study
15. Previous enrolment or randomisation of treatment in the present study.

Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes

Health Condition(s) or Problem(s) studied

non-ST and ST elevation acute coronary syndromes (ACS)
MedDRA version: 8.1 Level: HLT Classification code 10011085 Term: Ischaemic coronary artery disorders

Intervention(s)

Product Code: AZD6140 90 mg
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Ticagrelor
CAS Number: 274693-27-5
Current Sponsor code: AZD6140
Concentration unit: mg milligram(s)
Concentration number: 90-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use

Trade Name: Plavix 75 mg
Product Name: clopidogrel
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: clopidogrel
Concentration unit: mg milligram(s)
Concentration number: 75-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use

Primary Outcome(s)

Secondary Objective: - To assess the safety and tolerability of AZD6140 compared to clopidogrel.
- To assess the efficacy and safety of AZD6140 and clopidogrel in those patients
undergoing coronary artery bypass graft (CABG) surgery or percutaneous coronary intervention (PCI) during the study.
- To assess the occurrence of arrhythmic episodes detected by Holter monitoring during the initial period after randomization and at one month.

Main Objective: The primary objective of this study is to test that AZD6410 is superior to clopidogrel for prevention of vascular events (death from vascular causes, MI, stroke) in patients with non-ST or ST elevation acute coronary syndromes (ACS).

Primary end point(s): Time to the first occurrence of any event from the composite of death from vascular causes(*), myocardial infarction and stroke.
(*): Death from vascular causes includes CV deaths, cerebrovascular deaths, and any other death for which there was no clearly documented non-vascular cause.

Secondary Outcome(s)

Secondary ID(s)

2006-000658-27-GB

D5130C05262

Source(s) of Monetary Support

Secondary Sponsor(s)

Ethics review

Results

Results available:
Date Posted:
Date Completed:
URL:

Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.